SWSheila Weinmann

Sheila Weinmann

*This is an algorithmically generated author record based on publicly available information.

Sheila Weinmann has a total of 276 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cascade testing in an ovarian cancer traceback genetic testing program: The GRACE study experience

    by Jamilyn M. Zepp, Heather S. Feigelson, Yolanda K. Prado, Ana A. Reyes, Alan F. Rope, Jennifer K. Sawyer, Sheila Weinmann, Larissa L. White, Jessica Ezzell Hunter, Nora B. Henrikson

    Approximately 20% of individuals diagnosed with ovarian cancer (OC) have an inherited pathogenic or likely pathogenic variant (P/LP) in a cancer risk gene. Though genetic testing for hereditary cancer risk is currently recommended at OC diagnosis, individuals who have not received risk information and their at‐risk relatives (ARR) can benefit from genetic testing at any point. In a single‐arm implementation study, the Genetic Risk Assessment in Ovarian CancEr (GRACE) study offered traceback genetic testing using a panel of cancer risk genes to (1) living survivors with a prior OC diagnosis who had not received genetic testing at diagnosis and (2) first‐degree relatives of deceased eligible probands with a prior OC diagnosis who had not received genetic testing. For survivors and first‐degree relatives with a positive result (i.e., P/LP detected), we offered cascade testing to ARR, including providing support resources to facilitate communication with their relatives and offering to directly contact relatives. Traceback testing occurred on average 10–12 years from the incident OC diagnosis, resulting in 20 positive findings with 93 ARR eligible for cascade testing. Overall, cascade testing uptake was 38%, with similar rates among relatives of living (40%) and deceased (33%) probands. Cascade testing identified 11 individuals with OC‐risk variants and 3 incidental findings in genes not associated with OC risk. Women were more likely to complete cascade testing than men (45% vs. 30%, respectively). Initially, only two probands consented to direct contact with ARR by the study genetic counselor; 6 additional probands requested direct contact with relatives over subsequent interactions. These findings represent some of the first U.S. data available on cascade testing outcomes of traceback programs and suggest feasibility and effectiveness in U.S. health system settings.

  • Open Access

    Genetic Testing Uptake among Ovarian Cancer Survivors in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study

    by Larissa L. White, Jennifer K. Sawyer, Jamilyn M. Zepp, Yolanda K. Prado, Ana A. Reyes, Mahesh Maiyani, Elizabeth Shuster, Rachel Zucker, Nora B. Henrikson, Alan F. Rope, et al.

    Background: Recommendations state all people with ovarian cancers (OCs) receive genetic counseling, but testing uptake is only between 15 and 31%. Those with a prior diagnosis of OC who have not received genetic testing represent a missed opportunity for life-saving genetic risk information. The Genetic Risk Analysis in ovarian CancEr (GRACE) study aimed to evaluate the feasibility of the retrospective identification (“Traceback”) of individuals diagnosed with OC. Methods: This nonrandomized intervention study within two integrated health care systems identified participants with a history of OC between 1998 and 2020 who did not have genetic testing or testing limited to BRCA1/2. Participants received clinical genomic sequencing via a custom 60 gene panel. This study measured the feasibility of the Traceback methodology in OC survivors. Results: The initial cohort included 929 individuals, of which 57% had no prior genetic testing. Of the 302 eligible for recruitment, 88 consented to participate. We were able to outreach 97% of the eligible population using contact information from medical records. The stage at diagnosis was the only factor associated with consent. Of the 78 who returned their saliva sample, 21% had pathogenic/likely pathogenic variants, and 79% had negative results. Conclusion: The GRACE study resulted in a 29% uptake of genetic testing in OC survivors. The time since diagnosis did not have an impact on consent or ability to contact. GRACE can inform the implementation of future Traceback programs, providing guidance on how to prevent and mitigate the burden of OC and other hereditary cancers.


  • Open Access

    Medical imaging utilization and associated radiation exposure in children with down syndrome

    by Emily C Marlow, Jonathan M Ducore, Marilyn L Kwan, Erin J A Bowles, Robert T Greenlee, Jason D Pole, Alanna K Rahm, Natasha K Stout, Sheila Weinmann, Rebecca Smith-Bindman, et al.

    Objective: To evaluate the frequency of medical imaging or estimated associated radiation exposure in children with Down syndrome. Methods: This retrospective cohort study included 4,348,226 children enrolled in six U.S. integrated healthcare systems from 1996–2016, 3,095 of whom were diagnosed with Down syndrome. We calculated imaging rates per 100 person years and associated red bone marrow dose (mGy). Relative rates (RR) of imaging in children with versus without Down syndrome were estimated using overdispersed Poisson regression. Results: Compared to other children, children with Down syndrome received imaging using ionizing radiation at 9.5 times (95% confidence interval[CI] = 8.2–10.9) the rate when age <1 year and 2.3 times (95% CI = 2.0–2.5) between ages 1–18 years. Imaging rates by modality in children <1 year with Down syndrome compared with other children were: computed tomography (6.6 vs. 2.0, RR = 3.1[95%CI = 1.8–5.1]), fluoroscopy (37.1 vs. 3.1, RR 11.9[95%CI 9.5–14.8]), angiography (7.6 vs. 0.2, RR = 35.8[95%CI = 20.6–62.2]), nuclear medicine (6.0 vs. 0.6, RR = 8.2[95% CI = 5.3–12.7]), radiography (419.7 vs. 36.9, RR = 11.3[95%CI = 10.0–12.9], magnetic resonance imaging(7.3 vs. 1.5, RR = 4.2[95% CI = 3.1–5.8]), and ultrasound (231.2 vs. 16.4, RR = 12.6[95% CI = 9.9–15.9]). Mean cumulative red bone marrow dose from imaging over a mean of 4.2 years was 2-fold higher in children with Down syndrome compared with other children (4.7 vs. 1.9mGy). Conclusions: Children with Down syndrome experienced more medical imaging and higher radiation exposure than other children, especially at young ages when they are more vulnerable to radiation. Clinicians should consider incorporating strategic management decisions when imaging this high-risk population.


  • Open Access

    Abstract 1447: Feasibility of a traceback approach to facilitate genetic testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study

    by Heather S. Feigelson, Yolanda K. Prado, Tia Kauffman, Ana A. Reyes, Jamilyn M. Zepp, Mahesh Maiyani, Jennifer Sawyer, Larissa L. White, S. Bianca Salas, Sarah Vertrees, et al.

    Current guidelines state that genetic testing is clinically indicated for all individuals diagnosed with ovarian cancer. Individuals with a prior diagnosis of ovarian cancer who have not received genetic testing represent missed opportunities to identify individuals with inherited high risk cancer variants. The Genetic Risk Assessment in Ovarian Cancer (GRACE) study aims to address this significant healthcare gap using a “traceback testing” approach to identify individuals with a prior diagnosis of ovarian cancer and offer genetic risk information to them and their family members. Tumor registry data at two integrated health care systems (Kaiser Permanente Northwest and Kaiser Permanente Colorado) was used to identify individuals diagnosed with ovarian cancer from 2008 to 2019 who either did not receive genetic testing or had genetic testing limited to BRCA1 and BRCA2 and could benefit from more recent testing and testing using a comprehensive panel of cancer risk genes. Of the 180 eligible individuals contacted for participation, 51 have enrolled and consented to testing, reflecting an uptake rate of 28%. Of the 34 participants with genetic testing results, 7 (21%) have been found to carry a pathogenic or likely pathogenic variant in a cancer risk gene. The study genetic counselor supported these participants in sharing their genetic test results with at-risk relatives to facilitate cascade testing. Of the 20 at-risk relatives eligible for cascade testing, 10 have undergone genetic testing (50% cascade testing uptake) of which 4 have been found to carry the familial variant. Overall, these findings indicate the promise of such traceback testing approaches in providing potentially life-saving information to individuals and their family members at increased genetic risk for cancer who may otherwise be missed. Future efforts of the GRACE study will focus on the feasibility of leveraging archived pathology tissue to provide genetic risk information to family members of individuals with a diagnosis of ovarian cancer who are deceased. The GRACE study can inform broad implementation of future traceback programs across health care systems, providing life-saving information to prevent and mitigate the burden of ovarian and other hereditary cancers. Citation Format: Heather S. Feigelson, Yolanda K. Prado, Tia Kauffman, Ana A. Reyes, Jamilyn M. Zepp, Mahesh Maiyani, Jennifer Sawyer, Larissa L. White, S. Bianca Salas, Sarah Vertrees, Alan F. Rope, Sheila Weinmann, Nora B. Henrikson, Sandra S. Lee, Jessica E. Hunter. Feasibility of a traceback approach to facilitate genetic testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1447.


  • OP009: Feasibility of a traceback approach to facilitate genetic testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) study

    by Heather Feigelson, Yolanda Prado, Tia Kauffman, Ana Reyes, Jamilyn Zepp, Mahesh Maiyani, Jennifer Sawyer, Larissa White, S. Bianca Salas, Sarah Vertrees, et al.

  • Open Access

    Mammary collagen is under reproductive control with implications for breast cancer

    by Qiuchen Guo, Duanchen Sun, Alexander S. Barrett, Sonali Jindal, Nathan D. Pennock, Matthew W. Conklin, Zheng Xia, Elizabeth Mitchell, Ravikant Samatham, Naomi Mirza, et al.


  • Herpes zoster diagnosis and treatment in relation to incident dementia

    by Sheila Weinmann, Andreea Rawlings, Padma Koppolu, Yolanda K Prado, A Gabriela Rosales, Mark A Schmidt

    Background: Recent evidence suggests that some infectious diseases, such as herpes zoster (HZ), are positively associated with cognitive impairment and dementia, while certain anti‐viral medications have been reportedly associated with lower risk. We sought to evaluate associations between HZ diagnosis and treatment with incident dementia in a large, retrospective matched cohort.Method: Using ICD‐9 and ICD‐10 diagnosis codes in electronic medical records, we identified members of Kaiser Permanente Northwest who were age 50 and older between 2000‐2019 inclusive with a HZ diagnosis during this period. A comparison group without HZ diagnosis was individually matched 3:1 on age at HZ diagnosis date (index date), sex, and membership length prior to index date. We excluded subjects with dementia diagnosed before the index date. Follow‐up time started at the index date and ended on the date of dementia diagnosis (based on ICD‐9 and ICD‐10 codes), membership end date, death, or end of follow‐up, whichever came first. Medication for HZ was identified using the first anti‐viral pharmacy fill within 6 months before or after the index date. We used survival analysis to examine the associations between dementia and HZ diagnosis (yes/no, overall, by sex, age), HZ medication (yes/no), and HZ medication by tertiles of cumulative dose of medication dispensed. We adjusted models for demographic and clinical factors.Result: 109,830 persons (27,500 with HZ) were included. The mean age was 65.5 years, and 61.5% were female. Over a mean follow‐up of 6.3 years, 11,386 developed dementia. HZ diagnosis, overall or within subgroup, was not associated with higher risk of dementia (Figure). Among persons with HZ, receipt of anti‐viral medication (any vs. none) was not statistically associated with lower dementia risk. None of the hazard ratios for tertiles of cumulative anti‐viral dose was statistically significant, though the one for the highest tertile was suggestive.Conclusion: In our retrospective study of over 27,000 persons with HZ and matched comparison persons without HZ, we found no evidence for an association between HZ diagnosis and dementia. Anti‐viral medications prescribed around the time of the HZ diagnosis were not statistically associated with lower risk of dementia.

  • Open Access

    Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS)

    by Fredrik Wärnberg, Per Karlsson, Erik Holmberg, Kerstin Sandelin, Pat W. Whitworth, Jess Savala, Todd Barry, Glen Leesman, Steven P. Linke, Steven C. Shivers, et al.

    Prediction of radiotherapy (RT) benefit after breast-conserving surgery (BCS) for DCIS is crucial. The aim was to validate a biosignature, DCISionRT®, in the SweDCIS randomized trial. Women were randomly assigned to RT or not after BCS, between 1987 and 2000. Tumor blocks were collected, and slides were sent to PreludeDxTM for testing. In 504 women with complete data and negative margins, DCISionRT divided 52% women into Elevated (DS > 3) and 48% in Low (DS ≤ 3) Risk groups. In the Elevated Risk group, RT significantly decreased relative 10-year ipsilateral total recurrence (TotBE) and 10-year ipsilateral invasive recurrence (InvBE) rates, HR 0.32 and HR 0.24, with absolute decreases of 15.5% and 9.3%. In the Low Risk group, there were no significant risk differences observed with radiotherapy. Using a cutoff of DS > 3.0, the test was not predictive for RT benefit (p = 0.093); however, above DS > 2.8 RT benefit was greater for InvBE (interaction p = 0.038). Recurrences at 10 years without radiotherapy increased significantly per 5 DS units (TotBE HR:1.5 and InvBE HR:1.5). Continuous DS was prognostic for TotBE risk although categorical DS did not reach significance. Absolute 10-year TotBE and InvBE risks appear sufficiently different to indicate that DCISionRT can aid physicians in selecting individualized adjuvant DCIS treatment strategies. Further analyses are planned in combined cohorts to increase statistical power.


  • Positive predictive value and sensitivity of ICD‐9‐CM codes for identifying pediatric leukemia

    by Sheila Weinmann, Melanie C. Francisco, Marilyn L. Kwan, Erin J. A. Bowles, Alanna Kulchak Rahm, Robert T. Greenlee, Natasha K. Stout, Jason D. Pole, Lawrence H. Kushi, Rebecca Smith‐Bindman, et al.

    Background: To facilitate community‐based epidemiologic studies of pediatric leukemia, we validated use of ICD‐9‐CM diagnosis codes to identify pediatric leukemia cases in electronic medical records of six U.S. integrated health plans from 1996–2015 and evaluated the additional contributions of procedure codes for diagnosis/treatment.Procedures: Subjects (N = 408) were children and adolescents born in the health systems and enrolled for at least 120 days after the date of the first leukemia ICD‐9‐CM code or tumor registry diagnosis. The gold standard was the health system tumor registry and/or medical record review. We calculated positive predictive value (PPV) and sensitivity by number of ICD‐9‐CM codes received in the 120‐day period following and including the first code. We evaluated whether adding chemotherapy and/or bone marrow biopsy/aspiration procedure codes improved PPV and/or sensitivity.Results: Requiring receipt of one or more codes resulted in 99% sensitivity (95% confidence interval [CI]: 98–100%) but poor PPV (70%; 95% CI: 66–75%). Receipt of two or more codes improved PPV to 90% (95% CI: 86–93%) with 96% sensitivity (95% CI: 93–98%). Requiring at least four codes maximized PPV (95%; 95% CI: 92–98%) without sacrificing sensitivity (93%; 95% CI: 89–95%). Across health plans, PPV for four codes ranged from 84–100% and sensitivity ranged from 83–95%. Including at least one code for a bone marrow procedure or chemotherapy treatment had minimal impact on PPV or sensitivity.Conclusions: The use of diagnosis codes from the electronic health record has high PPV and sensitivity for identifying leukemia in children and adolescents if more than one code is required.


  • Open Access

    Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol

    by Tia L. Kauffman, Yolanda K. Prado, Ana A. Reyes, Jamilyn M. Zepp, Jennifer Sawyer, Larissa Lee White, Jessica Martucci, Suzanne Bianca Salas, Sarah Vertrees, Alan F. Rope, et al.

    Guidelines currently state that genetic testing is clinically indicated for all individuals diagnosed with ovarian cancer. Individuals with a prior diagnosis of ovarian cancer who have not received genetic testing represent missed opportunities to identify individuals with inherited high-risk cancer variants. For deceased individuals, post-mortem genetic testing of pathology specimens allows surviving family members to receive important genetic risk information. The Genetic Risk Assessment in Ovarian Cancer (GRACE) study aims to address this significant healthcare gap using a “traceback testing” approach to identify individuals with a prior diagnosis of ovarian cancer and offer genetic risk information to them and their family members. This study will assess the potential ethical and privacy concerns related to an ovarian cancer traceback testing approach in the context of patients who are deceased, followed by implementation and evaluation of the feasibility of an ovarian cancer traceback testing approach using tumor registries and archived pathology tissue. Descriptive and statistical analyses will assess health system and patient characteristics associated with the availability of pathology tissue and compare the ability to contact and uptake of genetic testing between patients who are living and deceased. The results of this study will inform the implementation of future traceback programs.